Phase 1 Retinal Vein Occlusion and Diabetic Macular Oedema Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are willing and able to follow the study procedures throughout the trial.
- People who are 18 years of age or older at the time of signing the consent form.
- People who have been clinically diagnosed with centre-involving diabetic macular oedema (a type of swelling in the central part of the retina related to diabetes).
- People whose blood sugar control measure (HbA1c, a blood test showing average blood sugar levels over time) is 10% or below.
- People whose best corrected vision (the best vision achievable with glasses or contact lenses) in the eye being studied scores 73 letters or fewer on a standard eye chart test.
Who may not be able to join:
- People who have any other eye disease (apart from the diabetic macular oedema described above) in the eye being studied that could affect vision improvement or would need treatment during the study, as determined by the trial investigator.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Xiaorong Li, Professor, Tianjin Medical University Eye Hospital
Phone: +862158206061
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Safety and tolerability after FT-003 injection
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.